Genmab A/S
Genmab A/S is a Danish biotechnology company focused on discovering and developing antibody medicines for cancer and other serious diseases. Its business spans proprietary antibody platforms, partnered commercial products, and a clinical pipeline of approved, late-stage, and earlier-stage programs, with operations across North America, Europe, and Asia.
Fiscal year 2025 · change from previous year
Development 2021–2025
Business
Share of revenueApproved therapies sold directly or through partners, plus related royalty streams.
Revenue from partnered products, milestones, and shared commercialization arrangements.
Late-stage and earlier-stage wholly owned and partnered antibody drug candidates.
Antibody engineering platforms used to create bispecifics, ADCs, and other modalities.
Customers
Genmab sells primarily into the global biopharmaceutical ecosystem rather than to end patients directly. Its revenue base is driven by pharmaceutical partners, licensees, and commercial collaborators that develop, market, or royalty-fund Genmab-originated antibody medicines. Where products are commercialized, the end demand comes from oncology patients treated through hospitals, oncology centers, and specialty pharmacies.
Large drug companies license Genmab assets, fund development, and commercialize partnered medicines.
Partners that sell Genmab-originated products and generate royalty income from net sales.
Biotech and pharma partners that share cost and expertise on late-stage studies.
Hospitals and cancer centers administer approved oncology products to patients.
Strategy
Genmab’s strategy centers on building and advancing antibody-based medicines through proprietary discovery platforms and selective partnerships. The company emphasizes late-stage pipeline expansion, especially in oncology, while using collaborators to broaden commercialization reach and convert approvals into durable royalty streams.
Later-stage programs are the main route to future approvals and self-owned value creation.
Partners provide scale in sales, medical affairs, and regional market access.
Bispecifics and ADCs can create differentiated oncology assets and broaden the pipeline.
Geography
Genmab is headquartered in Copenhagen, Denmark, and has an international operating footprint across North America, Europe, and Asia. Its business is global because antibody medicines are developed through multinational clinical trials and commercialized through regional pharma partners and healthcare systems. The company's exposure is therefore tied to regulatory approvals, partner execution, and treatment adoption across major oncology markets.
Risks
Genmab is exposed to clinical-development, regulatory, and manufacturing risk because its value depends on proving safety and efficacy in complex oncology programs. It also faces partner concentration, patent, and commercialization risks, since many products are marketed by others and royalty value depends on their execution and market uptake.
- Partner concentration and execution riskImpact: HighLikelihood: High
A meaningful part of value depends on third parties commercializing partnered medicines.
Exposure: Royalties and collaboration revenue
- Clinical development setbacksImpact: HighLikelihood: Medium
Antibody medicines must show acceptable safety and efficacy in trials before approval.
Exposure: Late-stage oncology pipeline
- Intellectual property riskImpact: HighLikelihood: Medium
Biologics depend on strong patent and proprietary platform protection for exclusivity.
Exposure: Antibody platforms and marketed products
- Manufacturing and quality riskImpact: MediumLikelihood: Medium
Complex biologic production can face batch, scale-up, or supply-chain issues.
Exposure: Commercial supply and clinical material
Accounting
Judgemental itemsPayments tied to partner sales, approvals, or development events can be recognized at different times.
Impact: Can cause uneven quarterly revenue and make trend analysis harder.
Purchased pipeline assets and integration charges affect comparability and future amortization.
Impact: May create intangible asset balances and non-recurring charges.
Drug candidates and acquired rights depend on clinical and commercial success assumptions.
Impact: Downward revisions can lead to material write-downs.
Development obligations, disputes, and provisions require management judgment.
Impact: Can affect liabilities and reported operating expense.
Similar listed companies
Publicly listed companies with a comparable business focus.
Xencor Inc
XNCR · Pharmaceutical Preparations
Evaxion A/S
EVAX · Biological Products, (No Diagnostic Substances)
Evaxion A/S is a clinical-stage biotech company focused on developing vaccines and other drug candidates using its AI-Immunology™ platform.
AnaptysBio, Inc
ANAB · Pharmaceutical Preparations
GENELUX Corp
GNLX · Pharmaceutical Preparations
GENELUX Corp is a U.S.-based clinical-stage biopharmaceutical company focused on developing oncolytic vaccinia virus immunotherapies, led by its Olvi-Vec program.
OmniAb, Inc.
OABI · Services-Commercial Physical & Biological Research
Alvotech
ALVO · Biological Products, (No Diagnostic Substances)
Alvotech is a U.S.-listed biotechnology company focused on developing and manufacturing biosimilar medicines.
Last updated: 24/10/2026